Indication
Prostatic carcinoma
Prostatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men. Read more about Prostatic carcinoma
8 drugs 8 manufacturers
Drugs that treat it
Common Prostatic carcinoma therapies.
EMCYT (estramustine phosphate sodium)
FLUTAMIDE
FLUTAMIDE
FLUTAMIDE
FLUTAMIDE
EMCYT (estramustine phosphate sodium)
EULEXIN (flutamide)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonProstatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men.
The vast majority of cases are adenocarcinomas that originate in the peripheral zone of the prostate gland and are typically driven by androgen receptor signaling.
While early-stage disease is frequently indolent and asymptomatic, progression can lead to lower urinary tract obstruction, hematuria, or metastatic dissemination predominantly to regional lymph nodes and the axial skeleton.
Pathophysiologically, it is characterized by glandular atypia, loss of basal epithelial cells, and variable histologic differentiation, which is clinically graded using the Gleason scoring system and monitored via serum prostate-specific antigen levels.
- cancer.gov
Prostatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men
- nih.gov
Prostatic carcinoma is a malignant epithelial neoplasm arising from the glandular tissue of the prostate, primarily affecting older men The vast majority of cases are adenocarcinomas that originate in the peripheral zone of the prostate gland and are typically driven by androgen receptor signaling Pathophysiologically, it is characterized by glandular atypia, loss of basal epithelial cells, and variable histologic differentiation, which is clinically graded using the Gleason scoring system and m...
- nih.gov
The vast majority of cases are adenocarcinomas that originate in the peripheral zone of the prostate gland and are typically driven by androgen receptor signaling While early-stage disease is frequently indolent and asymptomatic, progression can lead to lower urinary tract obstruction, hematuria, or metastatic dissemination predominantly to regional lymph nodes and the axial skeleton
- nih.gov
While early-stage disease is frequently indolent and asymptomatic, progression can lead to lower urinary tract obstruction, hematuria, or metastatic dissemination predominantly to regional lymph nodes and the axial skeleton
- nih.gov
Pathophysiologically, it is characterized by glandular atypia, loss of basal epithelial cells, and variable histologic differentiation, which is clinically graded using the Gleason scoring system and monitored via serum prostate-specific antigen levels
Personalize your experience
Follow Prostatic carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.